• 1
    NIH consensus conference. adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990; 264: 1444-1450.
  • 2
    Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990; 322: 352-358.
  • 3
    Hershman D, Hall MJ, Wang X, et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer. 2006; 107: 2581-2588.
  • 4
    Alberta Cancer Board. Early Stage Colon Cancer: Clinical Practice Guideline. Report No. GI_003. Edmonton, Alberta, Canada: Alberta Cancer Board; 2008.
  • 5
    Cree M, Tonita J, Turner D, et al. Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan, and Manitoba in 2004. Clin Colorectal Cancer. 2009; 8: 141-145.
  • 6
    Winget M, Hossain S, Yasui Y, Scarfe A. Characteristics of stage III colon adenocarcinoma patients who fail to receive guideline-recommended treatment. Cancer. 2010; 116: 4849-4856.
  • 7
    Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001; 93: 850-857.
  • 8
    Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA. 2005; 294: 2703-2711.
  • 9
    Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003; 21: 1293-1300.
  • 10
    Fritz A, Percy C, Jack A, et al. eds. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
  • 11
    Greene FL, Page DL, Fleming ID, et al. eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
  • 12
    World Health Organization. Rules and guidelines for morbidity and mortality coding (chap 4).International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Volume 2: Instruction Manual. Geneva, Switzerland: World Health Organization; 1994: 31-68.
  • 13
    Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43: 1130-1139.
  • 14
    Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999; 18: 695-706.
  • 15
    Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989; 8: 551-561.
  • 16
    Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol. 2002; 20: 3992-3998.
  • 17
    Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med. 2002; 136: 349-357.
  • 18
    Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001; 345: 1091-1097.
  • 19
    Zuckerman IH, Rapp T, Onukwugha E, et al. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with stage III colon cancer. J Am Geriatr Soc. 2009; 57: 1403-1410.
  • 20
    Gross CP, McAvay GJ, Krumholz HM, Paltiel AD, Bhasin D, Tinetti ME. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med. 2006; 145: 646-653.
  • 21
    Krzyzanowska MK, Regan MM, Powell M, Earle CC, Weeks JC. Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer. J Am Coll Surg. 2009; 208: 202-209.